9 Things to Know When Migraines With Aura Change or Worsen During Perimenopause
The aura piece is what trips so many women up — they've had migraines for years and assume perimenopause is just making the same old thing worse. What nobody told them is that 'with aura' is a different clinical category entirely, one that carries its own cardiovascular footnotes and changes the conversation about hormones completely. That distinction is worth knowing about before you walk into any appointment.
Learn more about Rose →Migraine with aura is neurologically distinct from migraine without aura — and the distinction matters here
Aura is caused by a phenomenon called cortical spreading depression, a slow wave of electrical suppression that moves across the brain's cortex and temporarily disrupts normal signalling. This process is associated with transient changes in cerebral blood flow and vessel reactivity, which is why migraine with aura carries different risk implications than migraine alone. Understanding this distinction is the foundation for everything else on this list — they are related conditions, but not the same condition.
Fluctuating estrogen — not low estrogen — is the primary migraine trigger in perimenopause
Estrogen has complex effects on serotonin pathways, trigeminal nerve sensitivity, and prostaglandin activity, all of which influence migraine threshold. In perimenopause, it is the erratic rise and fall of estrogen — rather than the eventual sustained low levels of postmenopause — that tends to destabilise migraine patterns most aggressively. This is why many women find their migraines actually improve after the final menstrual period, once estrogen settles at a consistently lower level.
New aura symptoms appearing for the first time in midlife should always be investigated by a doctor
When aura begins for the first time in perimenopause — particularly visual disturbances, sensory changes, or speech difficulties — it should not be assumed to be hormone-related without medical evaluation. Transient ischaemic attacks and other neurological events can mimic aura symptoms, and the risk of stroke does increase modestly in midlife for women. A clinician needs to rule out vascular causes before attributing new neurological symptoms to migraine.
Migraine with aura is an independent risk factor for ischaemic stroke, particularly in women
Large meta-analyses have confirmed that migraine with aura approximately doubles the relative risk of ischaemic stroke in women, compared to women without migraine. The absolute risk for most younger, otherwise healthy women remains low, but this background risk is why aura status is taken seriously in clinical decisions. This risk relationship does not disappear at menopause and is one of the reasons aura migraine warrants its own category in cardiovascular risk assessments.
Combined hormonal contraceptives are generally contraindicated in women with migraine with aura — and this extends to perimenopause
The combined oral contraceptive pill, patch, and vaginal ring all contain synthetic estrogen and are typically contraindicated in women with migraine with aura due to the additive stroke risk. This remains relevant in perimenopause because some women are still using combined contraception for cycle regulation or contraception during this stage. Switching to a progestogen-only method or non-hormonal contraception is the standard recommendation in this group.
Menopausal HRT is a different pharmacological category from the pill — the risk profile is not the same
A very common and understandable source of confusion is that women told they cannot take the pill due to aura migraines assume they also cannot take HRT. Menopausal HRT uses much lower doses of estrogen and, crucially, transdermal routes — patches, gels, and sprays — do not carry the same elevated clotting risk as oral estrogen because they bypass first-pass liver metabolism. The evidence on transdermal HRT and stroke risk in women with migraine with aura is reassuring, though not yet definitive.
Transdermal estrogen is generally considered the safer HRT route for women with migraine with aura
Current guidance from bodies including the British Menopause Society indicates that transdermal estrogen does not appear to carry the elevated venous thromboembolism or stroke risk associated with oral estrogen, making it the preferred route for women with additional vascular risk factors including aura migraine. Some women with migraine with aura find their attacks actually stabilise or decrease on steady-state transdermal HRT, because it avoids the hormonal peaks and troughs that trigger attacks. The decision remains an individual one, made with a clinician who knows the full picture.
Other cardiovascular risk factors compound the picture significantly
Migraine with aura does not exist in isolation, and its stroke risk implication is meaningfully higher when combined with other risk factors such as smoking, hypertension, obesity, or a family history of early cardiovascular disease. A woman with well-controlled blood pressure, no smoking history, and no other risk factors is in a very different position from someone with several compounding factors, even if both have aura migraines. Getting a full cardiovascular risk picture — including blood pressure monitoring — is an important part of any perimenopause review for this group.
Tracking pattern changes carefully gives both the woman and her clinician essential information
Migraine frequency, duration, aura characteristics, and relationship to the menstrual cycle or hormonal fluctuations are all clinically useful data points that most women are never asked to record systematically. A detailed migraine diary — including cycle day, sleep, stress, and any hormonal changes — can reveal whether attacks are estrogen withdrawal-driven, help identify triggers that are addressable, and provide objective evidence for HRT candidacy discussions. The pattern, not just the presence of migraines, is what informs the best path forward.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.